Biology subjects

Lawrenz, J.

Publications and source records attributed to Lawrenz, J..

3 recordsLinked to original sources

bioRxiv2026

APP and APLP2 Kunitz Domains Are Potent Endogenous Inhibitors of TMPRSS2 and Respiratory Virus Infection

Respiratory viruses depend on host proteases for activation of viral fusion proteins, making these enzymes attractive targets for broad-spectrum antiviral strategies. We previously identified Trypstatin, a human Bikunin-derived Kunitz domain, as a potent endogenous inhibitor of the airway serine protease TMPRSS2. Here, we investigated whether TMPRSS2 inhibition is shared by additional human Kunitz domains. Kunitz domains with high sequence similarity to Trypstatin were synthesized, refolded, and functionally characterized. Domains derived from amyloid precursor protein (APP) and amyloid precursor-like protein 2 (APLP2) potently inhibited TMPRSS2, with APP displaying subnanomolar activity comparable to camostat mesylate. APP and APLP2 selectively blocked SARS-CoV-2 Spike-mediated entry without affecting VSV-G-mediated entry or cell viability and inhibited infection by multiple coronaviruses and influenza viruses, but not TMPRSS2-independent rhinovirus. In primary human airway epithelial cultures, APP and Trypstatin reduced replication of SARS-CoV-2, endemic coronaviruses, and influenza A virus, and remained stable in airway mucus. These findings identify APP and APLP2 Kunitz domains as potent endogenous inhibitors of TMPRSS2-dependent respiratory virus infection and promising scaffolds for host-directed broad-spectrum antivirals.

microbiology↗

bioRxiv2025

Tonic interferons defend against respiratory viruses in primary human lung organoid-derived air-liquid interface cultures

Innate defences of the respiratory epithelium are the first barrier against incoming respiratory viruses. To understand the contribution of both basal (tonic) and induced interferon (IFN) to antiviral defences in a physiologically relevant system, we established air-liquid interface (ALI) cultures of primary human bronchial epithelium (HBE) and small airway epithelium (HSE). Via an organoid intermediate stage, the limited healthy donor material was expanded while preserving stemness and subsequently differentiated. Characterisation by spatial and transcriptomic analyses showed that the cellular diversity and architecture of our ALI cultures were comparable to native human lung epithelium. Upon infection with relevant human respiratory pathogens, such as Human Rhinovirus (HRV16) and human Coronaviruses (229E and NL63), only HRV16 induced a strong and early type I and III IFN response, leading to its eventual clearance from the cultures. Depletion of tonic type I/III IFNs using neutralising antibodies or scavengers reduced expression of levels of IFN-stimulated genes and increased infectious HRV production by [~]7-10-fold. Taken together, we present a method for generating primary lung epithelial cultures that retain their IFN status, demonstrate clearance of HRV by innate defences, and highlight the importance of tonic IFN in early antiviral defences. IMPORTANCEMild respiratory viral infections, for example, with human common cold coronaviruses or rhinoviruses, are a massive cause of human morbidity. The respiratory tract is the primary entry route for these viruses and also the contact site for initial innate immune defences. Here, we show that primary human lung epithelial cell-derived air-liquid interface cultures mimic the architecture and cell composition of native human lung epithelium, and retain both induced and tonic interferon (IFN) responses. Notably, our data show that the models innate immune defences are sufficient to clear human Rhinovirus (HRV) infections, which are characterised by rapid and robust IFN responses. Finally, depletion of tonic IFNs led to a marked increase in HRV infection. Thus, our research suggests that tonic low levels of IFNs contribute to the epithelial defence against viruses, maintaining the tissues immune readiness. Failure to maintain these tonic IFN levels increases the susceptibility towards infections.

microbiology↗

bioRxiv2025

Trypstatin as a Novel TMPRSS2 Inhibitor with Broad-Spectrum 1 Efficacy Against Corona and Influenza Viruses

Respiratory viruses, such as SARS-CoV-2 and influenza, exploit host proteases like TMPRSS2 for entry, making TMPRSS2 a prime antiviral target. Here, we report the identification and characterization of Trypstatin, a 61-amino acid Kunitz-type protease inhibitor derived from human hemofiltrate. Trypstatin inhibits TMPRSS2 and related proteases, with IC50 values in the nanomolar range, comparable to the small molecule inhibitor camostat mesylate. In vitro assays demonstrated that Trypstatin effectively blocks spike-driven entry of SARS-CoV-2, SARS-CoV-1, MERS-CoV, and hCoV-NL63, as well as hemagglutinin-mediated entry of influenza A and B viruses. In primary human airway epithelial cultures, Trypstatin significantly reduced SARS-CoV-2 replication and retained activity in the presence of airway mucus. In vivo, intranasal administration of Trypstatin to SARS-CoV-2-infected Syrian hamsters reduced viral titers and alleviated clinical symptoms. These findings highlight Trypstatins potential as a broad-spectrum antiviral agent against TMPRSS2-dependent respiratory viruses. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=182 SRC="FIGDIR/small/632953v1_ufig1.gif" ALT="Figure 1"> View larger version (25K): org.highwire.dtl.DTLVardef@1b90566org.highwire.dtl.DTLVardef@117293org.highwire.dtl.DTLVardef@1794959org.highwire.dtl.DTLVardef@1be9090_HPS_FORMAT_FIGEXP M_FIG C_FIG

microbiology↗